Reviewing Primary Sjögren's Syndrome: Beyond the Dryness - From Pathophysiology to Diagnosis and Treatment

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2017 Apr 4

PMID 28367079

Citations 78

Authors

Tim Both

Virgil A S H Dalm

P Martin van Hagen

Paul L A van Daele

Affiliations

Soon will be listed here.

Abstract

Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease, characterized by lymphocytic infiltration of the secretory glands. This process leads to sicca syndrome, which is the combination of dryness of the eyes, oral cavity, pharynx, larynx and/or vagina. Extraglandular manifestations may also be prevalent in patients with pSS, including cutaneous, musculoskeletal, pulmonary, renal, hematological and neurological involvement. The pathogenesis of pSS is currently not well understood, but increased activation of B cells followed by immune complex formation and autoantibody production are thought to play important roles. pSS is diagnosed using the American-European consensus group (AECG) classification criteria which include subjective symptoms and objective tests such as histopathology and serology. The treatment of pSS warrants an organ based approach, for which local treatment (teardrops, moistures) and systemic therapy (including non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, disease-modifying antirheumatic drugs (DMARDS) and biologicals) can be considered. Biologicals used in the treatment of pSS mainly affect the total numbers of B cells (B cell depletion (Rituximab)) or target proteins required for B cell proliferation and/or activation (e.g. B cell activating factor (BAFF)) resulting in decreased B cell activity. The aim of this review is to provide physicians a general overview concerning the pathogenesis, diagnosis and management of pSS patients.

Citing Articles

Diversity of central nervous system manifestations in Sjogren's Disease: a case-based review.

Jaskolska M, Rytlewska M, Dulak N, Ulanowski M, Kwarciany M, Wiglusz M Rheumatol Int. 2025; 45(2):35.

PMID: 39836271 PMC: 11750892. DOI: 10.1007/s00296-024-05753-8.

Obesity: Friend or Foe in Sjögren's Syndrome Patients?.

Mezei K, Nagy L, Orosz V, Aradi Z, Boi B, Szanto A Diagnostics (Basel). 2024; 14(23).

PMID: 39682633 PMC: 11640661. DOI: 10.3390/diagnostics14232725.

Evaluation of the Hypothalamic-Pituitary-Adrenal Axis in Patients with Primary Sjögren's Disease.

Glavina A, Zurak P, Martinovic D, Gotovac M, Supe-Domic D, Lugovic-Mihic L Medicina (Kaunas). 2024; 60(11).

PMID: 39597071 PMC: 11596132. DOI: 10.3390/medicina60111886.

The involvement of aquaporin 5 in the inflammatory response of primary Sjogren's syndrome dry eye: potential therapeutic targets exploration.

Fu L, Zhao Z, Zhao S, Zhang M, Teng X, Wang L Front Med (Lausanne). 2024; 11:1439888.

PMID: 39376655 PMC: 11456562. DOI: 10.3389/fmed.2024.1439888.

Gut microbiota and eye diseases: A review.

Zhao Y, Qiu P, Shen T Medicine (Baltimore). 2024; 103(39):e39866.

PMID: 39331938 PMC: 11441905. DOI: 10.1097/MD.0000000000039866.

References

Fox R, Kang H . Pathogenesis of Sjögren's syndrome. Rheum Dis Clin North Am. 1992; 18(3):517-38. View

Lehrer S, Bogursky E, Yemini M, Kase N, Birkenfeld A . Gynecologic manifestations of Sjögren's syndrome. Am J Obstet Gynecol. 1994; 170(3):835-7. DOI: 10.1016/s0002-9378(94)70294-2. View

Vazquez A, Khan M, Sanghvi S, Patel N, Caputo J, Baredes S . Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a population-based study from 1994 to 2009. Head Neck. 2014; 37(1):18-22. DOI: 10.1002/hed.23543. View

Ramos-Casals M, Tzioufas A, Font J . Primary Sjögren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis. 2004; 64(3):347-54. PMC: 1755414. DOI: 10.1136/ard.2004.025676. View

Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg J, Mariette X . Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis. 2006; 66(5):700-3. PMC: 1954605. DOI: 10.1136/ard.2006.060772. View

Roguedas A, Misery L, Sassolas B, Le Masson G, Pennec Y, Youinou P . Cutaneous manifestations of primary Sjögren's syndrome are underestimated. Clin Exp Rheumatol. 2004; 22(5):632-6. View

Drosos A, Andonopoulos A, Costopoulos J, Papadimitriou C, Moutsopoulos H . Prevalence of primary Sjögren's syndrome in an elderly population. Br J Rheumatol. 1988; 27(2):123-7. DOI: 10.1093/rheumatology/27.2.123. View

Mackay F, Schneider P, Rennert P, Browning J . BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2002; 21:231-64. DOI: 10.1146/annurev.immunol.21.120601.141152. View

Sakai A, Sugawara Y, Kuroishi T, Sasano T, Sugawara S . Identification of IL-18 and Th17 cells in salivary glands of patients with Sjögren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol. 2008; 181(4):2898-906. DOI: 10.4049/jimmunol.181.4.2898. View

10.

Delalande S, De Seze J, Fauchais A, Hachulla E, Stojkovic T, Ferriby D . Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore). 2004; 83(5):280-291. DOI: 10.1097/01.md.0000141099.53742.16. View

11.

Asmussen K, Andersen V, BENDIXEN G, Schiodt M, Oxholm P . A new model for classification of disease manifestations in primary Sjögren's syndrome: evaluation in a retrospective long-term study. J Intern Med. 1996; 239(6):475-82. DOI: 10.1046/j.1365-2796.1996.418817000.x. View

12.

Garcia-Carrasco M, Siso A, Ramos-Casals M, Rosas J, de la Red G, Gil V . Raynaud's phenomenon in primary Sjögren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol. 2002; 29(4):726-30. View

13.

Bendaoud B, Pennec Y, Lelong A, Le Noach J, Magadur G, Jouquan J . IgA-containing immune complexes in the circulation of patients with primary Sjögren's syndrome. J Autoimmun. 1991; 4(1):177-84. DOI: 10.1016/0896-8411(91)90016-6. View

14.

Gottenberg J, Cinquetti G, Larroche C, Combe B, Hachulla E, Meyer O . Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis. 2012; 72(6):1026-31. DOI: 10.1136/annrheumdis-2012-202293. View

15.

Fox R, Dixon R, Guarrasi V, Krubel S . Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus. 1996; 5 Suppl 1:S31-6. View

16.

Skoumal M, Wottawa A . Long-term observation study of Austrian patients with rheumatoid arthritis. Acta Med Austriaca. 2002; 29(2):52-6. DOI: 10.1046/j.1563-2571.2002.01043.x. View

17.

Sall K, Stevenson O, Mundorf T, Reis B . Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000; 107(4):631-9. DOI: 10.1016/s0161-6420(99)00176-1. View

18.

Belkhir R, Gestermann N, Koutero M, Seror R, Tost J, Mariette X . Upregulation of membrane-bound CD40L on CD4+ T cells in women with primary Sjögren's syndrome. Scand J Immunol. 2013; 79(1):37-42. DOI: 10.1111/sji.12121. View

19.

Fox R, Howell F, Bone R, Michelson P . Primary Sjogren syndrome: clinical and immunopathologic features. Semin Arthritis Rheum. 1984; 14(2):77-105. DOI: 10.1016/0049-0172(84)90001-5. View

20.

Kassan S, Moutsopoulos H . Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med. 2004; 164(12):1275-84. DOI: 10.1001/archinte.164.12.1275. View